V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330004027 | 330002001 | null | 63.9 | Adjuvant (A) | 2013-05-04 | 2013-05-10 | OST Euramos 1 Closed Trial - AP | N | N | 330015588 | MAP |
| 330004028 | 330009841 | 1.71 | 60 | Palliative (P) | 2013-03-29 | 2013-03-30 | CARBOPLATIN + GEMCITABINE | N | N | 330015595 | GEMCARBO |
| 330004029 | 330002002 | 1.7 | 63 | Adjuvant (A) | null | 2015-05-15 | Cisplatin + Etoposide (3 day) | null | null | 330015597 | CISPLATIN + ETOPOSIDE |
| 330004030 | 330007093 | null | 67.6 | Palliative (P) | 2014-08-20 | 2014-09-01 | GEMCARBO | N | N | 330015614 | GEMCARBO |
| 330004031 | 330007093 | 1.75 | 57.3 | Curative (C) | 2013-10-24 | 2013-10-24 | EURAMOS TRIAL | null | null | 330015614 | EURAMOS TRIAL |
| 330004032 | 330002003 | 1.65 | 102.9 | Curative (C) | 2013-10-17 | 2013-10-17 | Dox + HD Mtx (post PAM) | 02 | N | 330015637 | DOXORUBICIN + HD MTX |
| 330004033 | 330002004 | 1.66 | 49.5 | Neo-adjuvant (N) | 2013-09-27 | 2013-09-27 | EW EuroEwing 2012 Arm A VIDE | 02 | null | 330015638 | EURO-EWING |
| 330004034 | 330007094 | null | null | Neo-adjuvant (N) | 2017-06-14 | 2017-06-19 | Dox + HD Mtx (post PAM) | N | N | 330015651 | DOXORUBICIN + HD MTX |
| 330004035 | 330002005 | null | 101 | Palliative (P) | 2015-05-11 | 2015-05-11 | CARBOPLATIN + FLUOROURACIL | null | N | 330015657 | CARBO + FLUOROURACIL |
| 330004036 | 330002005 | null | 60.1 | Curative (C) | 2014-04-22 | 2014-04-22 | DA 3 + 10 | null | null | 330015657 | DA |
| 330004037 | 330002005 | 1.96 | null | Not known (9) | 2013-04-24 | 2013-05-01 | CVP R | N | N | 330015657 | CVP R |
| 330004038 | 330002006 | 1.59 | 94.2 | Curative (C) | 2016-05-07 | 2016-05-09 | Cetuximab + Radiotherapy Load | 02 | null | 330015666 | CETUXIMAB + RT |
| 330004039 | 330002007 | 1.77 | null | Curative (C) | 2017-08-31 | 2017-09-07 | Cetuximab + Radiotherapy Load | N | N | 330015668 | CETUXIMAB + RT |
| 330004040 | 330002007 | 1.68 | 118 | Palliative (P) | 2016-09-09 | 2016-09-13 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 330015668 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004041 | 330002007 | 1.71 | 101.3 | Curative (C) | null | 2018-01-23 | Cetuximab 7 day (Cycle 1) | N | N | 330015668 | CETUXIMAB |
| 330004042 | 330002007 | 1.79 | null | Disease modification (D) | 2017-11-23 | 2017-11-23 | Cyclophosphamide + Dex + Rituximab | 02 | N | 330015668 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004043 | 330002007 | 1.51 | 69.6 | Palliative (P) | 2013-10-30 | 2013-11-05 | GemCarbo Days 1+8 | N | N | 330015668 | GEMCARBO |
| 330004044 | 330002008 | 1.7 | 62 | Not known (9) | 2017-02-23 | 2017-02-23 | Cyclophosphamide + Dex + Rituximab | N | N | 330015679 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004045 | 330002008 | 1.48 | 82.7 | Disease modification (D) | 2014-04-19 | 2014-06-16 | Cyclophosphamide + Dex + Rituximab | N | N | 330015679 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004046 | 330002009 | 2.01 | null | Curative (C) | 2013-06-10 | 2013-06-20 | EURAMOS TRIAL | N | N | 330015697 | EURAMOS TRIAL |
| 330004047 | 330007098 | 1.78 | 58 | Adjuvant (A) | 2017-05-20 | 2017-06-01 | CAP | 02 | N | 330015698 | CAP |
| 330004048 | 330007098 | 1.69 | 55 | Curative (C) | 2017-02-02 | 2017-02-10 | DA 3+8 | 2 | N | 330015698 | DA |
| 330004049 | 330007098 | 1.69 | 48.4 | Neo-adjuvant (N) | 2016-07-16 | 2016-08-14 | EW EuroEwing 2012 Arm A VIDE | N | N | 330015698 | EURO-EWING |
| 330004050 | 330007098 | 1.81 | 72 | Curative (C) | 2014-02-26 | 2014-02-28 | CARBOPLATIN + FLUOROURACIL | 2 | N | 330015698 | CARBO + FLUOROURACIL |
| 330004051 | 330007098 | 1.21 | 96.4 | Adjuvant (A) | 2017-05-28 | 2017-05-28 | CVP R | N | N | 330015698 | CVP R |
| 330004052 | 330007098 | 1.83 | 74 | Palliative (P) | 2013-08-07 | 2013-08-20 | Cyclophosphamide + Dex + Rituximab | N | N | 330015698 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004053 | 330002010 | 1.49 | 88.6 | Curative (C) | 2014-11-01 | 2014-12-25 | Cetuximab 7 day (Cycle 1) | null | Y | 330015736 | CETUXIMAB |
| 330004054 | 330002011 | 1.8 | 113 | Curative (C) | 2013-09-21 | 2013-09-21 | OST Euramos 1 Closed Trial - AP | N | N | 330015750 | MAP |
| 330004055 | 330007099 | 1.75 | 98 | Disease modification (D) | 2015-11-16 | 2015-12-04 | CVP R | 2 | null | 330015754 | CVP R |
| 330004056 | 330009846 | 1.62 | 85.7 | Curative (C) | null | 2013-10-13 | Dox + HD Mtx (post PAM) | null | null | 330015757 | DOXORUBICIN + HD MTX |
| 330004057 | 330011371 | 1.56 | 63.5 | Palliative (P) | 2016-06-13 | 2016-06-19 | EW EuroEwing 2012 Arm A VIDE | 02 | N | 330015770 | EURO-EWING |
| 330004058 | 330002012 | 1.6 | 57.8 | Palliative (P) | 2014-04-25 | 2014-04-25 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 330015778 | CISPLATIN + GEMCITABINE |
| 330004059 | 330002013 | null | 50.4 | Curative (C) | 2016-09-27 | 2016-10-12 | DA | null | N | 330015792 | DA |
| 330004060 | 330002014 | 1.67 | 78.2 | Curative (C) | 2013-05-29 | 2013-05-29 | Cetuximab 7 day (Cycle 1) | Y | Y | 330015800 | CETUXIMAB |
| 330004061 | 330007100 | 1.8 | 87 | null | 2015-06-19 | 2015-06-19 | Cetuximab + Radiotherapy Maint | N | N | 330015804 | CETUXIMAB + RT |
| 330004062 | 330007100 | 1.81 | 69.4 | Curative (C) | 2015-12-31 | 2016-01-01 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 330015804 | CARBO + FLUOROURACIL |
| 330004063 | 330007100 | 1.56 | 47.9 | Curative (C) | 2016-02-08 | 2016-02-08 | EW EuroEwing 99 : VIDE | 02 | N | 330015804 | EURO-EWING |
| 330004064 | 330007100 | 1.49 | 79.3 | Curative (C) | 2016-10-26 | 2016-11-08 | DA 3+8 | N | N | 330015804 | DA |
| 330004066 | 330002016 | 1.67 | 32 | Adjuvant (A) | 2015-09-05 | 2015-09-15 | EW EuroEwing 99 : VIDE | Y | N | 330015847 | EURO-EWING |
| 330004067 | 330002016 | 0 | 60.8 | Neo-adjuvant (N) | null | 2015-01-16 | EW EuroEwing 2012 Arm A VIDE | null | null | 330015847 | EURO-EWING |
| 330004068 | 330002016 | 1.58 | 59 | Palliative (P) | 2015-05-23 | 2015-05-24 | CISPLATIN + ETOPOSIDE | 02 | N | 330015847 | CISPLATIN + ETOPOSIDE |
| 330004069 | 330002017 | 1.67 | 60.9 | Palliative (P) | 2016-06-08 | 2016-07-07 | CVP R | null | null | 330015859 | CVP R |
| 330004070 | 330002018 | 1.62 | 55.8 | Palliative (P) | 2016-11-03 | 2016-11-10 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 330015862 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004071 | 330002019 | 1.78 | 54 | Curative (C) | 2015-07-07 | 2015-07-15 | PAM | N | N | 330015864 | MAP |
| 330004072 | 330002019 | 1.78 | 51.2 | Disease modification (D) | 2018-03-01 | 2018-03-01 | CVP R | 02 | N | 330015864 | CVP R |
| 330004073 | 330002019 | 1.73 | 89.999 | Neo-adjuvant (N) | 2015-10-14 | 2015-10-22 | EW EuroEwing 2012 Arm A VIDE | null | N | 330015864 | EURO-EWING |
| 330004074 | 330011373 | null | 61.2 | Neo-adjuvant (N) | 2016-07-30 | 2016-08-20 | Dox + HD Mtx (post PAM) | N | N | 330015882 | DOXORUBICIN + HD MTX |
| 330004075 | 330012207 | 1.61 | null | Neo-adjuvant (N) | 2018-09-21 | 2018-10-01 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 330015886 | CISPLATIN + GEMCITABINE |
| 330004076 | 330012207 | 1.7 | 52.9 | Curative (C) | 2017-11-04 | 2017-11-10 | PAM x 2 pre-surgery (cycles 1&2) | N | N | 330015886 | MAP |
| 330004077 | 330002020 | 1.74 | 88.4 | Disease modification (D) | 2016-02-14 | 2016-02-16 | CVP R | 02 | N | 330015898 | CVP R |